Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Patients with refractory cancers and their caregivers/families will have access to optimised, tailored and affordable immunotherapeutic interventions that increase their quality of life, across European regions, EU Member States and Associated Countries; Healthcare professionals and academia will have access to clinical evidence, on effectiveness of immunotherapeutic interventions, to deploy evidence-based treatment interventions with improved patient selection that improve outcomes in real life, i.e. in routine healthcare, for patients with refractory cancers who often present with co-morbidities; National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries will have the evidence to implement and reimburse optimised and affordable immunotherapeutic interventions in their healthcare systems, including in everyday medical practice. Scope: While cancer research and innovation have generated novel treatment options, patients with refractory cancers across Europe need access to more effective, affordable and tailored cancer immunotherapeutic interventions which keep up with increasing demands in a complex and fragmented oncology healthcare landscape with spiralling healthcare costs. Pragmatic clinical trials focus on choosing between care options. Pr…bron

De eisen uit de regeling. Uw situatie bepaalt of u voldoet; dit is geen beschikking.

Zoals beschreven door de verstrekker. Onvolledig? Controleer altijd het officiële loket.

• Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancersEU-portaal (SEDIA) · ec.europa.eu7 jul 2026
  Toon brontekst

  Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
  
  Topic: HORIZON-MISS-2026-02-CANCER-03
  Call: HORIZON-MISS-2026-02 — Supporting the implementation of the Cancer Mission
  Programma: Horizon Europe (2021 - 2027)
  
  == Beschrijving ==
  Expected Outcome:
  Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes:
  Patients with refractory cancers and their caregivers/families will have access to optimised, tailored and affordable immunotherapeutic interventions that increase their quality of life, across European regions, EU Member States and Associated Countries;
  Healthcare professionals and academia will have access to clinical evidence, on effectiveness of immunotherapeutic interventions, to deploy evidence-based treatment interventions with improved patient selection that improve outcomes in real life, i.e. in routine healthcare, for patients with refractory cancers who often present with co-morbidities;
  National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries will have the evidence to implement and reimburse optimised and affordable immunotherapeutic interventions in their healthcare systems, including in everyday medical practice.
  Scope:
  While cancer research and innovation have generated novel treatment options, patients with refractory cancers across Europe need access to more effective, affordable and tailored cancer immunotherapeutic interventions which keep up with increasing demands in a complex and fragmented oncology healthcare landscape with spiralling healthcare costs.
  Pragmatic clinical trials focus on choosing between care options. Pragmatic trials evaluate effectiveness of interventions in settings that more closely resemble routine, real-world settings, aiming to produce evidence directly applicable to clinical practice[1].
  Proposals should address all the following:
  Conduct randomised or cluster-randomised academic investigator-initiated[2] pragmatic clinical trials that benefit patients with refractory cancers - at any stage of the disease, for any cancer subtype, in any age group or part of society - to deliver effective, affordable and tailored immunotherapeutic interventions for implementation by healthcare systems at the level of local communities, European regions, EU Member States and Associated Countries.
  All data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of socio-economic status or ethnicity. Translational research is limited to supporting biomarker-informed patient stratification and the conduct and analyses of the proposed clinical trial(s).
  The primary and secondary endpoints of the pragmatic clinical trials should target overall survival, patient-reported outcomes and quality of life issues considered important by and for cancer patients and their caregivers/families. Such endpoints should be defined together with patients and their caregivers/families through research that stimulates social innovation and supports end-user engagement using participative research models.
  The chosen treatment intervention(s) should be adapted to the particular needs of the target population and to the specificities of the provision of care at local, regional, or national level, duly reflecting the diversity across EU Member States and Associated Countries. Furthermore, affordability and accessibility should be taken into account.
  Applicants should include an appropriate mix of stakeholders from various disciplines, sectors[3] and regional as well as national health authorities, and provide details of the clinical study(ies) in the dedicated annex using the template provided in the submission system.
  The successful proposals are expected to build on resources made available by the Knowledge Centre on Cancer (KCC)[4] to foster EU alignment and coordination.
  Successful proposals will be asked to join the 'Diagnosis and Treatment' cluster for the EU Cancer Mission[5] and should include a budget for networking, attendance at meetings, and joint activities[6]. The Commission will facilitate coordination of these activities.
  [1] Some examples: treatment versus active surveillance in patient management, combination of treatment interventions, determination of optimal dose and dose schedule, de-escalation of treatment intervention, comparative effectiveness of different treatment interventions.
  [2] Clinical trials in which a health technology (e.g. a medicinal product, a medical device, an in-vitro diagnostic medical device, a surgical or other medical intervention) is tested in humans, independently from commercial interest and for public health benefits.
  [3] such as physicians, academia, patients and their caregivers, patient representatives, engineers, behavioural scientists, SMEs, business networks, insurance companies, charities and foundations, research organisations, civil society.
  [4] Hosted by the European Commission's Joint Research Centre (JRC). Especially through the ’European Guidelines and Quality Assurance Schemes for Breast, Colorectal and Cervical Cancer Screening and Diagnosis‘, and the ’European Cancer Information System (ECIS)’ and the ’European Cancer Inequalities Registry (ECIR), see https://knowledge4policy.ec.europa.eu/cancer_en
  [5] To address the objectives of the EU Cancer Mission, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of EU Cancer Mission R&I and policy actions.
  [6] Examples of those activities are research or research capacity, organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Proposals are not required to include details of these activities, as they will be defined during the grant agreement preparation and during the life of the project.
  
  == Voorwaarden (topic conditions) ==
  ">
  General conditions
  1. Admissibility Conditions: Proposal page limit and layout
  described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
  Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
  2. Eligible Countries
  described in Annex B of the Work Programme General Annexes.
  A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
  3. Other Eligible Conditions
  described in Annex B of the Work Programme General Annexes.
  4. Financial and operational capacity and exclusion
  described in Annex C of the Work Programme General Annexes.
  5a. Evaluation and award: Award criteria, scoring and thresholds
  are described in Annex D of the Work Programme General Annexes.
  5b. Evaluation and award: Submission and evaluation processes
  The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.
  are described in Annex F of the Work Programme General Annexes and the Online Manual.
  5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
  described in Annex F of the Work Programme General Annexes.
  6. Legal and financial set-up of the grants
  Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf]].
  The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
  described in Annex G of the Work Programme General Annexes.
  Specific conditions
  described in the [specific topic of the Work Programme]
  Application and evaluation forms and model grant agreement (MGA):
  Application form templates — the application form specific to this call is available in the Submission System
  Standard application form (HE RIA, IA)
  Guidance
  HE Programme Guide
  Model Grant Agreements (MGA)
  Lump Sum MGA
  Call-specific instructions
  Detailed budget table (HE LS)
  Information on clinical studies (HE)
  Guidance: "Lump sums - what do I need to know?"
  Additional documents:
  HE Main Work Programme 2026-2027 – 1. General Introduction
  HE Main Work Programme 2026-2027 – 12. Missions
  HE Main Work Programme 2026-2027 – 15. General Annexes
  HE Programme Guide
  HE Framework Programme 2021/695
  HE Specific Programme Decision 2021/764
  EU Financial Regulation 2024/2509
  Decision authorising the use of lump sum contributions under the Horizon Europe Programme
  Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
  EU Grants AGA — Annotated Model Grant Agreement
  Funding & Tenders Portal Online Manual
  Funding & Tenders Portal Terms and Conditions
  Funding & Tenders Portal Privacy Statement